Literature DB >> 20495815

Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Antonio G Tristano1.   

Abstract

Anti-tumor necrosis factor alpha (TNF-alpha) drugs have been successfully used for the treatment of rheumatic autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, ankylosing spondylitis (AS), juvenile chronic arthritis, and Crohn's disease. However, they have been associated with different neurological disorders, including alterations of peripheral nerves, multiple sclerosis (MS), optic neuritis (ON) and acute transverse myelitis (ATM). This article reviews the most current aspect regarding neurological adverse events associated with anti-TNF-alpha drugs with emphasis on the possible explanations for this relation and the pathogenic mechanism of TNF-alpha in neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495815     DOI: 10.1007/s00415-010-5591-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  93 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

2.  Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue.

Authors:  M C Morganti-Kossman; P M Lenzlinger; V Hans; P Stahel; E Csuka; E Ammann; R Stocker; O Trentz; T Kossmann
Journal:  Mol Psychiatry       Date:  1997-03       Impact factor: 15.992

Review 3.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Authors:  G Kollias; E Douni; G Kassiotis; D Kontoyiannis
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

4.  Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers.

Authors:  C Richez; P Blanco; A Lagueny; T Schaeverbeke; J Dehais
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

5.  Etanercept and demyelinating disease in a patient with psoriasis.

Authors:  Sean A Sukal; Lakshmi Nadiminti; Richard D Granstein
Journal:  J Am Acad Dermatol       Date:  2006-01       Impact factor: 11.527

Review 6.  Demyelination and inhibition of tumor necrosis factor (TNF).

Authors:  M D Magnano; W H Robinson; M C Genovese
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

7.  Distal lower extremity paresthesia and foot drop developing during adalimumab therapy.

Authors:  Cindy N Berthelot; Saira J George; Sylvia Hsu
Journal:  J Am Acad Dermatol       Date:  2005-11       Impact factor: 11.527

8.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

Review 9.  TNF receptor subtype signalling: differences and cellular consequences.

Authors:  David J MacEwan
Journal:  Cell Signal       Date:  2002-06       Impact factor: 4.315

10.  Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy.

Authors:  Fabrizia Terenghi; Silvia Allaria; Eduardo Nobile-Orazio
Journal:  J Peripher Nerv Syst       Date:  2006-03       Impact factor: 3.494

View more
  25 in total

1.  Aseptic meningitis in a patient receiving treatment with anti-tumour necrosis factor alpha.

Authors:  Alexander J Hamilton; Nicholas J Gutowski
Journal:  J Neurol       Date:  2010-12-31       Impact factor: 4.849

2.  Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.

Authors:  Ali Theibich; Lene Dreyer; Melinda Magyari; Henning Locht
Journal:  Clin Rheumatol       Date:  2013-11-08       Impact factor: 2.980

3.  Iatrogenic transverse myelitis in a patient with rheumatoid arthritis.

Authors:  Pournamy Sarathchandran; Ayman Alboudi; Reem AlSuwaidi; Abubaker AbdulRahman Almadani
Journal:  BMJ Case Rep       Date:  2019-03-20

4.  Extensive and severe CNS demyelination associated with golimumab therapy.

Authors:  Elisabeth Maillart; Caroline Papeix; Charles Mellerio; Anne Bertrand; Catherine Lubetzki; Céline Louapre
Journal:  J Neurol       Date:  2016-07-25       Impact factor: 4.849

5.  Autoimmune-like syndromes during TNF blockade: does infection have a role?

Authors:  Joerg C Prinz
Journal:  Nat Rev Rheumatol       Date:  2011-03-29       Impact factor: 20.543

6.  Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis.

Authors:  Laura Fionda; Fiammetta Vanoli; Antonella Di Pasquale; Luca Leonardi; Stefania Morino; Giovanni Antonini
Journal:  J Neurol       Date:  2018-05-16       Impact factor: 4.849

7.  [Intraocular inflammation in multiple sclerosis].

Authors:  N Stübiger; K Ruprecht; U Pleyer
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

8.  Psoriasis during natalizumab treatment for multiple sclerosis.

Authors:  Jorge Millán-Pascual; Laura Turpín-Fenoll; Pablo Del Saz-Saucedo; Ignacio Rueda-Medina; Santiago Navarro-Muñoz
Journal:  J Neurol       Date:  2012-10-25       Impact factor: 4.849

9.  First case of demyelinating polyneuropathy probably related to treatment with golimumab.

Authors:  Francisco Javier Domínguez Díez
Journal:  Eur J Rheumatol       Date:  2018-06-22

10.  TNF-α/TNFR2 Regulatory Axis Stimulates EphB2-Mediated Neuroregeneration Via Activation of NF-κB.

Authors:  Paul D Pozniak; Armine Darbinyan; Kamel Khalili
Journal:  J Cell Physiol       Date:  2015-11-04       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.